Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Next Previous
X
Search
Trial Profile

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Cabazitaxel (Primary) ; Capivasertib (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Niraparib (Primary) ; Darolutamide; Radium 223 chloride
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ProBio

    • Most Recent Events

    • 11 Jan 2024 Number of treatment arms are increased from 6 to 8.
    • 24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, Enrollment in the experimental group was stopped when the Bayesian probability of superiority reached prespecified thresholds (''graduation'').
    • 24 Oct 2023 Results (n=219) assessing efficacy; progression-free survival, from following treatment arms (ARPi; abiraterone and enzalutamide and taxanes) and taxanes (docetaxel and cabazitaxel) presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top